C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

04 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

19 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

23 фев 2023 07:00:02 Источник Nasdaq GlobeNewswire

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

08 фев 2023 07:00:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

30 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

09 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

03 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

29 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

26 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04 авг 2022 08:00:03 Источник Nasdaq GlobeNewswire

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors

02 авг 2022 08:00:03 Источник Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

16 май 2022 08:00:01 Источник Nasdaq GlobeNewswire

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 май 2022 08:00:02 Источник Nasdaq GlobeNewswire

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

08 апр 2022 13:00:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

16 мар 2022 16:05:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

09 мар 2022 08:00:01 Источник Nasdaq GlobeNewswire

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 

08 мар 2022 16:30:00 Источник Nasdaq GlobeNewswire

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

24 фев 2022 07:00:03 Источник Nasdaq GlobeNewswire

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

10 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire